Prime Medicine, Inc.
PRME · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,983 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2,983 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $155,289 | $147,905 | $86,725 | $70,550 |
| G&A Expenses | $50,161 | $43,387 | $29,819 | $13,924 |
| SG&A Expenses | $50,161 | $43,387 | $29,819 | $13,924 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $13,500 | $0 | $0 |
| Operating Expenses | $205,450 | $204,792 | $116,544 | $84,474 |
| Operating Income | -$202,467 | -$204,792 | -$116,544 | -$84,474 |
| % Margin | -6,787.4% | – | – | – |
| Other Income/Exp. Net | $6,585 | $6,380 | -$6,225 | -$81,379 |
| Pre-Tax Income | -$195,882 | -$198,412 | -$122,769 | -$165,853 |
| Tax Expense | $0 | -$279 | -$948 | -$486 |
| Net Income | -$195,882 | -$198,133 | -$121,821 | -$165,367 |
| % Margin | -6,566.6% | – | – | – |
| EPS | -1.652 | -2.178 | -1.461 | -1.923 |
| % Growth | 24.2% | -49.1% | 24% | – |
| EPS Diluted | -1.652 | -2.178 | -1.461 | -1.923 |
| Weighted Avg Shares Out | 118,600 | 90,969 | 97,209 | 95,730 |
| Weighted Avg Shares Out Dil | 118,600 | 90,969 | 97,209 | 95,730 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,522 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6,128 | $4,653 | $2,224 | $568 |
| EBITDA | -$196,339 | -$186,639 | -$114,320 | -$83,906 |
| % Margin | -6,581.9% | – | – | – |